Literature DB >> 32606188

Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis.

Takeshi Numata1, Takeo Endo1, Hidetoshi Yanai1, Kyoko Ota1, Yusuke Yamamoto2, Kei Shimizu2, Hideyasu Yamada3, Kenji Hayashihara4, Shinichiro Okauchi5, Hiroaki Satoh6, Yutaka Yamada7, Tomohiro Tamura7, Kazuto Saito8, Norihiro Kikuchi9, Koichi Kurishima10, Hiroichi Ishikawa10, Hiroko Watanabe11, Toshihiro Shiozawa12, Nobuyuki Hizawa12, Yasunori Funayama13, Shigen Hayashi14, Hiroyuki Nakamura15, Takaaki Yamashita16.   

Abstract

AIM: To clarify the correlation between serum levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA) and metastasis and survival in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: CEA and CYFRA levels in 131 ALK-rearranged NSCLC patients were determined using fluorescence in situ hybridization (FISH), real time-reverse transcription polymerase chain reaction, and immunohistochemistry, using biopsy specimens, cytology specimens, and plasma specimens. Cut-off value of each marker was determined as 10 ng/ml.
RESULTS: In logistic regression analysis, higher levels of both markers had a positive relationship with bone metastases, and higher levels of CYFRA was relevant to liver metastases, and multiple-organ metastases. However, these markers were not proven to be poor prognostic factors in Cox's proportional model analysis.
CONCLUSION: Elevated serum CEA and CYFRA levels seem to provide useful clinical information about presence of bone and liver metastasis and multiple-organ metastases, although they were not a powerful indicator of prognosis. These two markers may suggest the extension of metastasis and would be helpful in considering treatment options. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  ALK rearranged NSCLC; CEA; CYFRA; Serum tumor markers; carcinoembryonic antigen; cytokeratin 19 fragment; distant metastasis; non-small cell lung cancer

Mesh:

Substances:

Year:  2020        PMID: 32606188      PMCID: PMC7439905          DOI: 10.21873/invivo.12013

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  32 in total

1.  CEA and survival in patients with stage IA-B NSCLC.

Authors:  H Ishikawa; H Satoh; Y T Yamashita; M Ohtsuka; K Sekizawa
Journal:  Thorac Cardiovasc Surg       Date:  2002-08       Impact factor: 1.827

2.  Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.

Authors:  Sufei Wang; Pei Ma; Guanzhou Ma; Zhilei Lv; Feng Wu; Mengfei Guo; Yumei Li; Qi Tan; Siwei Song; E Zhou; Wei Geng; Yanran Duan; Yan Li; Yang Jin
Journal:  Eur J Cancer       Date:  2019-11-07       Impact factor: 9.162

3.  Serum Carcinoembryonic Antigen Levels Before the First Curative Hepatectomy for Metastatic Colorectal Cancer Is a Predictor of Recurrence.

Authors:  Hidejiro Kawahara; Seiya Yoshida; Yoichi Tohyama; Satoru Yanagisawa; Takeyuki Misawa; Katsuhiko Yanaga
Journal:  Anticancer Res       Date:  2018-09       Impact factor: 2.480

4.  Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream.

Authors:  Helga Sertić Milić; Ana Franjević; Gordana Bubanović; Ante Marušić; Igor Nikolić; Igor Puljić
Journal:  Wien Klin Wochenschr       Date:  2015-04-28       Impact factor: 1.704

5.  Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.

Authors:  Kentaro Ito; Osamu Hataji; Hiroyasu Kobayashi; Atsushi Fujiwara; Masamichi Yoshida; Corina N D'Alessandro-Gabazza; Hidetoshi Itani; Motoaki Tanigawa; Takuya Ikeda; Kentaro Fujiwara; Hajime Fujimoto; Tetsu Kobayashi; Esteban C Gabazza; Osamu Taguchi; Nobuyuki Yamamoto
Journal:  J Thorac Oncol       Date:  2016-08-04       Impact factor: 15.609

6.  Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study.

Authors:  Shinichiro Okauchi; Takeshi Numata; Takeshi Nawa; Hideo Ichimura; Takefumi Saito; Kenji Hayashihara; Hideyasu Yamada; Hiroaki Satoh; Takeshi Endo; Yoshihisa Inage; Takayuki Kaburagi; Moriyuki Kiyoshima; Yutaka Yamada; Tomohiro Tamura; Kazuhito Saito; Masaharu Inagaki; Nobuyuki Hizawa; Yukio Sato; Toshihiro Shiozawa; Ikuo Sekine; Hiroichi Ishikawa; Koichi Kurihima; Mitsuaki Sakai; Koichi Kamiyama; Masaki Kimura; Norihiro Kikuchi; Hiroyuki Nakamura; Kinya Furukawa; Takahide Kodama; Kunihiko Miyazaki; Takaaki Yamashita; Shigen Hayashi; Yasunori Funayama; Akihiro Nomura
Journal:  Anticancer Res       Date:  2020-02       Impact factor: 2.480

7.  Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.

Authors:  Hisashi Suzuki; Shigemi Ishikawa; Hiroaki Satoh; Hiroichi Ishikawa; Mitsuaki Sakai; Tatsuo Yamamoto; Masataka Onizuka; Yuzuru Sakakibara
Journal:  Eur J Cardiothorac Surg       Date:  2007-08-17       Impact factor: 4.191

Review 8.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

9.  Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

Authors:  Renaud Descourt; Maurice Perol; Gaëlle Rousseau-Bussac; David Planchard; Bertrand Mennecier; Marie Wislez; Alexis Cortot; Florian Guisier; Loïck Galland; Pascal Dô; Roland Schott; Eric Dansin; Jennifer Arrondeau; Jean-Bernard Auliac; Christos Chouaid
Journal:  Lung Cancer       Date:  2019-08-14       Impact factor: 5.705

10.  Is there any correlation between levels of serum ostepontin, CEA, and FDG uptake in lung cancer patients with bone metastasis?

Authors:  A K Ayan; B Erdemci; E Orsal; Z Bayraktutan; E Akpinar; A Topcu; M Turkeli; B Seven
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2015-10-27       Impact factor: 1.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.